11-108330281-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PP3_Moderate
The NM_000051.4(ATM):c.7375C>G(p.Arg2459Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000204 in 1,614,040 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2459C) has been classified as Uncertain significance.
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.7375C>G | p.Arg2459Gly | missense_variant | 50/63 | ENST00000675843.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.7375C>G | p.Arg2459Gly | missense_variant | 50/63 | NM_000051.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000394 AC: 6AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251258Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135788
GnomAD4 exome AF: 0.0000185 AC: 27AN: 1461844Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727224
GnomAD4 genome ? AF: 0.0000394 AC: 6AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74338
ClinVar
Submissions by phenotype
not provided Uncertain:5
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 25, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 25, 2021 | The frequency of this variant in the general population, 0.000087 (3/34588 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals affected with breast (PMIDs: 33128190 (2021) and 35264596 (2022)), ovarian (PMIDs: 24448499 (2014) and 26689913 (2015)), colorectal (PMID: 28135145 (2017)), prostate (PMID: 33436325 (2021)), and lung cancers (PMID: 28843361 (2017)), as well as in an individual who met clinical criteria for neurofibromatosis type 1 (NF1) (PMID: 28051113 (2017)). In a large scale breast cancer association study, the variant was observed in control individuals and breast cancer cases (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/ATM)). In addition, this variant was observed with 2 other pathogenic ATM variants in an individual affected with ataxia-telangiectasia (AT) (PMID: 21665257 (2011)), which suggests this variant may not be the primary cause of disease. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Uncertain significance, no assertion criteria provided | clinical testing | Franklin by Genoox | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2022 | ATM: PM1, PP3 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 30, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23585524, 24448499, 27067391, 28051113, 28843361, 26689913, 28135145, 26898890, 29752822, 33280026, 32365829, 33128190, 21665257, 33471991, 26580448, 23532176, 32986223, 33436325, 35264596) - |
Hereditary cancer-predisposing syndrome Uncertain:4
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Jan 13, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Spanish ATM Cancer Susceptibility Variant Interpretation Working Group | Jun 17, 2020 | The c.7375C>G (p.Arg2459Gly) variant has an allele frequency of 0.000017 (0.002%, 4/236726 alleles) in the gnomAD v2.1.1 non-cancer dataset, with a maximal frequency of 0.000088 (0.009%, 3/34256 alleles) in the Latino / Admixed American subpopulation (no population frequency criterion met; http://gnomad.broadinstitute.org). This missense variant is not predicted to lead to a splicing alteration as per SPiCE predictor and no splicing site is created/activated according to at least 3 splicing predictors of the set SpliceSiteFinderlike - MaxEntScan - NNSplice – GeneSplicer, but it alters the protein function / structure on the in-silico prediction reports of REVEL and PROVEAN (PP3). There is no other supporting data that meet criteria for consideration. Therefore, the clinical significance of this variant is uncertain. Adapted ACMG/AMP rules applied as defined by the Spanish ATM working group: PP3 (PMID: 33280026). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 18, 2023 | The p.R2459G variant (also known as c.7375C>G), located in coding exon 49 of the ATM gene, results from a C to G substitution at nucleotide position 7375. The arginine at codon 2459 is replaced by glycine, an amino acid with dissimilar properties. This variant has been detected in multiple hereditary cancer cohorts including individuals with breast and/or ovarian cancer, colorectal cancer, prostate cancer and acute lymphoblastic leukemia (Kanchi KL et al. Nat. Commun. 2014;5:3156; Zhang J et al. N Engl J Med, 2015 Dec;373:2336-2346; Mucaki EJ et al. BMC Med Genomics, 2016 Apr;9:19; Yurgelun MB et al. J Clin Oncol, 2017 Apr;35:1086-1095; Gomes R et al. Breast Cancer Res Treat, 2021 Feb;185:851-861; Karlsson Q et al. Eur Urol Oncol, 2021 Aug;4:570-579; Sandoval RL et al. PLoS One, 2021 Feb;16:e0247363; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). In one study, this variant was reported in 12/60,466 breast cancer cases but also detected in 5/53,461 healthy controls (Dorling et al. N Engl J Med. 2021 02;384:428-439). This variant has also been detected in a patient with ataxia telangiectasia (AT); however, this patient also carried 2 other mutations in the ATM gene, and the phase (cis or trans) of these alterations was not noted (Micol R et al. J Allergy Clin Immunol, 2011 Aug;128:382-9.e1). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 15, 2022 | This missense variant replaces arginine with glycine at codon 2459 of the ATM protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. In a large international case-control study, this variant was reported in 12/60454 breast cancer cases and 5/53456 controls (OR=2.122, 95%CI 0.748 to 6.024, p-value=0.223; PMID: 33471991). This variant has been observed in individuals affected with breast cancer (PMID: 33128190, 33280026, 33471991; Color Health internal data), ovarian cancer (PMID: 24448499, 26689913, 33280026), lung cancer (PMID: 28843361), and colorectal cancer (PMID: 28135145; Color Health internal data). In addition, this variant has been observed in an individual affected with neurofibromatosis type 1, who also carried a CDKN2A whole gene deletion (PMID: 28051113). This variant has also been reported in an individual affected with ataxia-telangiectasia, although this individual was also found to have two co-occurring ATM mutations in trans (PMID: 21665257). This variant has been identified in 5/251258 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Ataxia-telangiectasia syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Jan 29, 2024 | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 2459 of the ATM protein (p.Arg2459Gly). This variant is present in population databases (rs730881383, gnomAD 0.006%). This missense change has been observed in individual(s) with ovarian cancer, colorectal cancer, and breast cancer and ataxia telangiectasia (PMID: 21665257, 24448499, 26689913, 27067391, 28135145, 29752822, 32986223). ClinVar contains an entry for this variant (Variation ID: 181982). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 13, 2021 | - - |
Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 27, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at